Form 4: Arvinas CEO Teel Boosts Stake with RSU and Option Grants

Arvinas, Inc. President and CEO Randy Teel received significant equity awards, including 147,791 restricted stock units and options for 218,691 shares, as part of the company's 2018 Stock Incentive Plan.

Summary

• Randy Teel, President and CEO, and a Director of Arvinas, Inc., was granted equity awards on February 26, 2026.
• The awards include 147,791 Restricted Stock Units (RSUs) and options to purchase 218,691 shares of common stock.
• The RSUs were granted at a price of $0 and represent a contingent right to receive one share of common stock upon settlement.
• The stock options have an exercise price of $13.38 per share.
• Both the RSUs and stock options will vest over a four-year period, with one-quarter vesting on February 12, 2027, and the remainder vesting annually or monthly thereafter through February 12, 2030, contingent on continued service.
• Following these transactions, Randy Teel beneficially owns 297,487 shares of common stock and 218,691 stock options.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates continued executive commitment and aligns management incentives with long-term company performance, which is generally favorable for shareholders.

Positives

• The grant of restricted stock units and stock options aligns the interests of President and CEO Randy Teel with long-term shareholder value.
• The vesting schedule over four years encourages long-term commitment and performance from key management.
• The awards are part of a standard incentive plan, indicating ongoing executive compensation practices.

Risks

• The vesting of these equity awards is subject to Randy Teel's continued service with Arvinas, Inc., meaning the awards could be forfeited if employment ceases before vesting dates.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the vesting schedules of the granted equity awards, which extend through February 2030.

Industry Context

StockSavvy.ai notes that equity grants to executive leadership, such as those detailed for Arvinas's CEO, are a common practice in the biotechnology and pharmaceutical sectors. These grants are typically designed to incentivize long-term performance and retention, aligning executive interests with shareholder returns, particularly in companies focused on long-term drug development cycles.

Stakeholder Impact

• Shareholders: The grants align management's interests with long-term shareholder value, potentially fostering sustained performance.
• Employees: May signal stability in executive leadership and standard compensation practices within the company.

Next Steps

• Continued service by Randy Teel with Arvinas, Inc. to ensure vesting of equity awards.
• Future vesting events for RSUs and stock options on specified dates through February 2030.

Key Dates

Recommendation

This Form 4 filing details a routine equity grant to the CEO, which is a standard compensation practice designed to align executive interests with long-term shareholder value. While positive for management retention and incentive, it does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment stance. Therefore, a 'hold' recommendation is appropriate, maintaining current positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

Arvinas, ARVN, Randy Teel, SEC Form 4, Insider Trading, Equity Grant, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Beneficial Ownership, Stock Incentive Plan